- Home
- / Aratana Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Aratana Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$35.4 M
FY, 2018
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|
| Revenue | 123.0K | 767.0K | 678.0K | 38.6M | 25.6M | 35.4M |
| Revenue growth, % | 523.6% | -11.6% | 5586.0% | |||
| Cost of goods sold | 108.0K | 333.0K | 365.0K | 3.1M | 16.4M | 6.8M |
| Gross profit | 15.0K | 434.0K | 313.0K | 35.4M | 9.2M | 28.6M |
| Gross profit margin, % | 12.2% | 56.6% | 46.2% | 91.9% | 35.9% | 80.8% |
| General and administrative expense | 8.6M | 17.9M | 19.8M | 27.3M | 28.9M | 28.8M |
| Operating expense total | 19.9M | 42.0M | 89.8M | 66.2M | 53.6M | 40.5M |
| Depreciation and amortization | 380.0K | 1.9M | 1.5M | 379.0K | 350.0K | 517.0K |
| EBIT | (19.9M) | (41.6M) | (89.5M) | (30.8M) | (44.5M) | (11.9M) |
| EBIT margin, % | -16148.8% | -5424.9% | -13200.0% | -79.9% | -173.8% | -33.6% |
| Interest income | 75.0K | 123.0K | 189.0K | 385.0K | 449.0K | 666.0K |
| Interest expense | 121.0K | 1.4M | 3.7M | 2.8M | 3.1M | 2.8M |
| Pre tax profit | (19.7M) | (40.3M) | (85.8M) | (33.6M) | (47.5M) | (14.7M) |
| Income tax expense | (15.5M) | (1.4M) | (1.7M) | |||
| Net Income | (4.3M) | (38.8M) | (84.1M) | (33.6M) | (47.5M) | (14.7M) |